[
1. Gai X, Li S, Wei Y, Yu S. A case report about oligodendrogliomas of the fourth ventricle. Medicine (Baltimore). 2018 Apr;97(17):e0594.10.1097/MD.0000000000010594
]Search in Google Scholar
[
2. Koeller KK, Rushing EJ. From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation. Radiogr a Rev Publ Radiol Soc North Am Inc. 2005;25(6):1669–88.10.1148/rg.256055137
]Search in Google Scholar
[
3. Liu D. Tumors and Cancers Central and Peripheral Nervous Systems. In: 1st Edition. Boca Raton: CRC Press; 2017. p. 47–51.10.1201/9781315120522-9
]Search in Google Scholar
[
4. Schwab M. Encyclopedia of Cancer. In: 4th ed. Berlin: Springer; 2017. p. 610–1.10.1007/978-3-662-46875-3
]Search in Google Scholar
[
5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumors of the Central Nervous System. Revised 4th ed. Lyon, FR: International Agency for Research on Cancer; 2016. p. 60-74.
]Search in Google Scholar
[
6. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol. 2003 Nov;60(5):443–56.10.1016/S0090-3019(03)00167-8
]Search in Google Scholar
[
7. Smits M. Imaging of oligodendroglioma. Br J Radiol. 2016;89(1060):20150857.10.1259/bjr.20150857484621326849038
]Search in Google Scholar
[
8. Haaga JR, Boll DT. CT and MRI of the Whole Body. Vol I. 6th ed. Philadelphia, PA: Elsevier; 2017. p. 191.
]Search in Google Scholar
[
8. Haaga JR, Boll D. Computed Tomography & Magnetic Resonance Imaging Of The Whole Body E-Book: Elsevier Health Sciences; 2016, p191.
]Search in Google Scholar
[
9. Wesseling P, van den Bent M, Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015 Jun;129(6):809–27.10.1007/s00401-015-1424-1443669625943885
]Search in Google Scholar
[
10. Pai T, Epari S, Desai S, Wadile A, Gupta T, Goda JS, et al. Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion. Neurol India. 2017;65(1):113–20.10.4103/0028-3886.19819528084254
]Search in Google Scholar
[
11. Lass U, Nümann A, von Eckardstein K, Kiwit J, Stockhammer F, Horaczek JA, et al. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. PLoS One. 2012;7(7):e41298.10.1371/journal.pone.0041298340251322844452
]Search in Google Scholar
[
12. Tuffaha M, Guski H, Kristiansen G. Immunohistochemestry in Tumor Diagnostics. In: Cham C, editor. Springer; 2018. p. 236.10.1007/978-3-319-53577-7
]Search in Google Scholar
[
13. Pouget C, Hergalant S, Lardenois E, Lacomme S, Houlgatte R, Carpentier C, et al. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network. Brain Pathol. 2020 May;30(3):465–78.10.1111/bpa.12788
]Search in Google Scholar
[
14. Takano S, Ishikawa E, Sakamoto N, Matsuda M, Akutsu H, Noguchi M, et al. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathol. 2016 Apr;33(2):107–16.10.1007/s10014-016-0260-x26968173
]Search in Google Scholar
[
15. Liu S, Liu X, Xiao Y, Chen S, Zhuang W. Prognostic factors associated with survival in patients with anaplastic oligodendroglioma. PLoS One. 2019;14(1):e0211513.10.1371/journal.pone.0211513635319330699183
]Search in Google Scholar
[
16. van den Bent MJ, Chang SM. Grade II and III Oligodendroglioma and Astrocytoma. Neurol Clin. 2018 Aug;36(3):467–84.10.1016/j.ncl.2018.04.00530072066
]Search in Google Scholar
